Antibody Profiling of COVID-19 Patients in an Urban Low-Incidence Region in Northern Germany

  1. Werner Solbach
  2. Julia Schiffner
  3. Insa Backhaus
  4. David Burger
  5. Ralf Staiger
  6. Bettina Tiemer
  7. Andreas Bobrowski
  8. Timothy Hutchings
  9. Alexander Mischnik

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.3389/fpubh.2020.570543
  2. ScreenIT

    SciScore for 10.1101/2020.05.30.20111393: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementConsent: Of these 162 index cases, 140 gave their written informed consent to participate and for a total of 110 patients, results from blood samples were available (Fig. 2).
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Experimental Models: Cell Lines
    SentencesResources
    The data sheet reports cross-reactivities with SARS-CoV-1, but not with MERS-CoV, HCoV-229E, HCoV-NL63, HCoVHKU-1 or HCoV-OC43 virus.
    HCoV-NL63
    suggested: RRID:CVCL_RW88)
    Software and Algorithms
    SentencesResources
    Statistical analyses were conducted using SPSS version 26.0.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    There are few limitations in our study. Cross-reactivity could possibly be a limitation of immunoassays. On the one hand, our test was validated with a sensitivity of 89-100 % and a specificity of 87.5 – 95.5 % for IgA and 83.5 – 97.5 % for IgG and a recent study has demonstrated negligible cross-reactivity from other human coronavirus NL63 to SARS-CoV-215, 25. Our study does not give information on protective antibody functions with regard to resistance to re-infection and reduction of transmissibility of the virus. The results on the neutralisation capacity are not present till now. Based on the development of IgG antibody dynamics, however, it might be reasonable to assume that ratios beyond 2 might confer protection.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.05.30.20111393 on medRxiv